Advanced Drug Delivery Technologies for Enhancing Bioavailability and Efficacy of Risperidone

Abstract

Ritu Rathi,1 Nitin Martandrao Mehetre,1 Shuchi Goyal,1 Inderbir Singh,1 Kampanart Huanbutta,2 Tanikan Sangnim3 1Chitkara College of Pharmacy, Chitkara University, Patiala, PB, India; 2Department of Manufacturing Pharmacy, College of Pharmacy, Rangsit University, Pathum Thani, Thailand; 3Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, ThailandCorrespondence: Tanikan Sangnim, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Burapha University, 169, Seansook, Muang, Chonburi, 20131, Thailand, Email [email protected]: Multidisciplinary research has been conducted on novel drug delivery technologies to maximize therapeutic advantages while curtailing undesirable reactions. Drugs under BCS Class II often have a low bioavailability because the dissolution phase limits the absorption efficiency. In this review, risperidone was used as a pharmacological model to examine the impact of solubility enhancement at the primary administration site for such pharmaceuticals. For tackling drug-related pertains like disease diagnostics, therapy, and prophylactic measures at the cellular or molecular levels, implementing nanocarriers in therapeutics has significant potential. The comprehensive pharmaceutical compositions of risperidone nano-microparticles that have been developed to alleviate psychosis are highlighted in the study, which also illustrates potential future developments in such domains.Keywords: nanoparticles, risperidone, psychosis, micro particulates, bioavailability

Keywords

• nanoparticles
• risperidone
• psychosis
• micro particulates
• bioavailability